Kathrin S. W.
- Country
- Austria
- Department
- 1. Med. Abteilung
Research Overview
Data & Insights
Has run more than one trial at 0 of 228 partner sites.
Specializations
Hormone Receptor Positive Breast Cancer
The investigator concentrates on ER+/HER2- early breast cancer, aiming to refine therapeutic pathways for this subtype.
- Hormone receptor biology
- HER2-negative disease phenotypes
- Adjuvant treatment optimization
Research integrates molecular profiling with therapeutic decision‑making.
CDK4/6 Inhibition
Focus is placed on the therapeutic impact of CDK4/6 inhibitors combined with endocrine therapy in early disease.
- Palbociclib efficacy
- Combination regimens
- Resistance mechanisms
Evaluates long‑term disease‑free survival benefits.
Selective Estrogen Receptor Degraders (SERDs)
Investigation of novel oral SERDs such as camizestrant to enhance endocrine strategies.
- Camizestrant pharmacology
- Abemaciclib synergy
- Recurrence prevention
Aims to establish superiority over standard endocrine options.
Adjuvant Endocrine Therapy Strategies
Studies extended duration of endocrine therapy in the adjuvant setting to improve outcomes.
- Five‑year endocrine courses
- Therapeutic sequencing
- Patient adherence
Seeks to define optimal treatment length for high‑risk patients.
Clinical Outcomes Measurement
Utilizes endpoints such as invasive disease‑free survival to gauge treatment impact.
- iDFS assessment
- Recurrence risk modeling
- Survival benefit quantification
Supports evidence‑based guideline updates.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.